Dystrophies and heart disease

Current Opinion in Cardiology

Volumn 12, Issue 3, 1997, Pages 329-343

  Cox, Gerald F ^a   Kunkel, Louis M ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECKER MUSCULAR DYSTROPHY; CARDIOMYOPATHY; CELL MEMBRANE; CONGESTIVE HEART FAILURE; DUCHENNE MUSCULAR DYSTROPHY; HEART DILATATION; MOLECULAR GENETICS; MYOTONIC DYSTROPHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0030981051     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199705000-00015     Document Type: Review

References (112)

1. Dubowitz V: Muscle biopsy: a practical approach. In The Muscular Dystrophies. London: Bailliére Tindall; 1985:289-404.
2. Bushby KMD: Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC consortium on limb-girdle dystrophies. Neuromuscular Dis 1995, 5:71-74.
3. Bushby KM, Beckmann JS: The limb girdle muscular dystrophies: proposal for a new nomenclature. Neuromuscul Drsord 1995, 4:337-343.
4. Arahata R, Ishii H, Hayashi YK: Congenital muscular dystrophies. Curr Opin Neurol 1995, 8:385-390.
5. Engel AG, Yamamoto M, Fischbeck KH: Dystrophinopathies. In Myology. edn 2. Edited by Engel AG, Franzini-Armstrong C. New York: McGraw Hill; 1994:1133-1187.
6. Sadoulet-Puccio HM, Kunkel LM: Dystrophin and its isoforms. Brain Pathol 1996, 6:25-35. An up-to-date review of dystrophin's gene structure, isoform expression, and protein domains.
7. Worton R: Muscular dystrophies: diseases of the dystrophin-glycoprotein complex. Science 1995, 270:755-756. A concise review of the dystrophin-glycoprotein complex and its role as the cause of several muscular dystrophies.
8. Bonnemann CG, McNally EM, Kunkel LM: Beyond dystrophin: current progress in the muscular dystrophies. Curr Opin Pediatr 1997, 8:569-582.
9. Ozawa E, Yoshida M, Hagiwara Y, Suzuki A, Mizuno Y, Noguchi S: Dystrophin-associated proteins in muscular dystrophy. Hum Mol Genet 1995, 4:1711-1716.
10. Ahn AH, Kunkel LM: The structural and functional diversity of dystrophin. Nature Genet 1993, 3:283-291.
11. Tinsley JM, Blake DJ, Zuollig RA, Davies KE: Increasing complexity of the dystrophin-associated protein complex. Proc Natl Acad Sci USA 1994, 91:8307-8313.
12. Hoffman EP, Brown RJ, Kunkel LM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987, 51:919-928.
13. Muntoni F, Wilson L, Marrosu G, Marrosu MG, Cianchetti C, Mestroni L, Ganau A, Dubowitz V, Sewry C: A mutation in the dystrophin gene selectively affecting dystrophin expression in the heart. J Clin Invest 1995, 96:693-699.
14. Milasin J, Muntoni F, Severini M, Bartolini L, Vatta M, Krajinovic M, Mateddu A, Angelini C, Camerini F, Falaschi A, et al.: A point mutation in the 5′ splice site of the dystrophin gene first intron responsible for X-linked dilated cardiomyopathy. Hum Mol Genet 1996, 5:73-79. Previous reports had shown that deletions involving muscle exon 1 and intron 1 of the dystrophin gene can cause XLDCM. These authors show that a single point mutation in the dystrophin gene can suppress the expression of full-length dystiophin in the heart and upregulate the expression of nonmuscle isoforms of dystrophin in skeletal muscle. Notably. the proband had a normal creatine phosphokinase, whereas his brother had a mildly elevated serum creatine phosphokinase and myopathic muscle biopsy.
15. Towbin JA, Hejtmancik JF, Brink P. Gelb B, Zhu XM, Chamberlain JS, McCabe ERB. Swift M: X-linked dilated cardiomyopathy: molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993, 87:1854-1993.
16. Franz WM, Cremer M, Herrmann R, Grunig E, Fogel W, Scheffold T, Goebel HH, Kircheisen R, Kubler W, Voit T, Katus HA: X-linked dilated cardiomyopathy: novel mutation of the dystrophin gene. Ann N Y Acad Sci 1996, 752:470-491. Unlike previously reported XLDCM families who had an absence of cardiac dystrophin with upregulation of nonmuscle isoforms in skeletal muscle, this family was found to express dystrophin in both cardiac and skeletal muscle, albeit in reduced amounts. The dystrophin was qualitatively abnormal, with a loss of antibody binding in the middle rod domain. The mutation was not identified.
17. Beggs AH, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F, Angelini C, Sugita H, Kunkel LM: Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet 1991, 49:54-67.
18. Perloff JK, Roberts WC, de Leon AC Jr, O'Doherty D: The distinctive electrocardiogram of Duchenne's progressive muscular dystrophy. Am J Med 1967, 42:179-188.
19. Nigro G, Comi LI, Politano L, Bain RJI: The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy, Int J Cardiol 1990, 26:271-277.
20. Nigro G, Comi LI, Politano L, Limogelli FM, Nigro V, De Rimini ML, Giugliano MAM, Petretta VR, Passamano L, Restucci B, et al.: Evaluation of the cardiomyopathy in Becker muscular dystrophy. Muscle Nerve 1995, 18:283-291.
21. Melacini P, Fanin M, Danieli GA, Villanova C, Matinello F, Miorin M, Freda MP, Miorelli M, Mostacciuolo ML, Fasoli G, et al.: Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. Circulation 1996, 94:3168-3175.
22. Saito M, Kawai H, Akaike M, Adachi K, Nishida Y, Saito S: Cardiac dysfunction in Becker muscular dystrophy. Am Heart J 1996, 132:642-647. A comparison of electrocardiographic and echocardiographic data from 21 BMD and 43 DMD patients leads these authors to propose that cardiac disease progression differs in these two allelic disorders.
23. Quinlivan RM, Dubowitz V: Cardiac transplantation in Becker muscular dystrophy. Neuromuscular Dis 1992, 2:165-167.
24. Nigro G, Politano L, Nigro V, Petratta VR, Comi LI: Mutation of the dystrophin gene and cardiomyopathy. Neuromuscul Disord 1994, 4:371-379.
25. Politano L, Nigro V, Nigro G, Petretta VR, Paasamano L, Papparella S, Di Somma S, Corni LI: Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. JAMA 1996, 275:1335-1338. Cardiac assessment of 152 DMD and 45 BMD female carriers over a 10-year period reveals a surprisingly high frequency of cardiac involvement, which progresses over time and is similar to that seen in affected male patients. The authors suggest that dystrophin testing should be considered in women with idiopathic cardiomyopathy.
26. Hoffman EP, Arahata K, Minetti C, Bonilla E, Rowland LP: Dystrophinopathy in isolated cases of myopathy in females. Neurology 1992, 42:967-975.
27. Muntoni F, Melis M, Ganau A, Dubowitz V: Transcription of the dystrophin gene in normal tissues and in skeletal muscle of a family with X-linked dilated cardiomyopathy. Am J Hum Genet 1995, 56:151-157.
28. Muntoni F, Cau M, Ganau A, Congui R, Arvedi G, Mateddu A, Marrosu M, Cianchetti C, Realdi G, Cao A, Melis M: Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med 1993, 329:921-925.
29. Cox GA, Sunada Y, Campbell KP, Chamberlain JS: Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy. Nature Genet 1994, 8:333-339.
30. Greenberg DS, Sunada Y, Campbell KP, Yaffe D, Nudel U: Exogenous Dp71 restores the levels of dystrophin associated proteins but does not alleviate muscle damage in mdx mice. Nature Genet 1994, 8:340-344.
31. Klamut HJ, Bosnoyan-Collins LO, Worton RG, Ray PN, Davis HL: Identification of a transcriptional enhancer within muscle intron 1 of the human dystrophin gene. Hum Mol Genet 1996, 5:1599-1606. These authors discover a transcriptional regulatory sequence that is located in the same region of the dystrophin gene as mutations that cause XLDCM.
32. Yoshida K, Ikeda S, Nakamura A, Kagoshima M, Takeda S, Shoji S, Yanagisawa N: Molecular analysis of the Duchenne muscular dystrophy gene in patients with Becker muscular dystrophy presenting with dilated cardiomyopathy. Muscle Nerve 1993, 16:1161-1166.
33. Koenig M, Huffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987, 50:509-517.
34. Koenig M, Monaco AP, Kunkel LM: The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 1988, 53:219-226.
35. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL: Dystrophin protects the sarcolemma from stress developed during muscle contraction. Proc Natl Acad Sci U S A 1993, 90:3710-3714.
36. Brenman JE, Chao DS, Xia H, Aldape X, Bredt DS: Nitric oxide synthase completed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 1995, 82:743-752.
37. Song KS, Scherer PE, Tang Z, Okamoto T, Li S, Chatel M, Chu C, Kohtz DS, Lisanti MP Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells: caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem 1996, 271:15160-15165. These authors present biochemical and immunocytochemical evidence that caveolin and dystrophin are associated. This finding connects dystrophin to signal transduction pathways and possibly calcium regulation.
38. Noguchi S, McNally EM, Ben Othmane K, Hagiwara Y, Mizuno Y, Yoshida M, Yamamoto H, Bönnemann CG, Gussoni E, Denton PH, et al.: Mutations in the dystrophin-associated protein γ-sarcoglycan in chromosome 13 muscular dystrophy. Science 1995, 270:819-822. Another dystrophin-associated protein is found to be a cause of autosomal recessive LGMD.
39. Tomé FM, Evangelista T, Leclerc A, Sunada Y, Manole E, Estornet B, Barois A, Campbell KP, Fardeau M: Congenital muscular dystrophy with merosin deficiency. C R Acad Sci III (Paris) 1994, 317:251-357.
40. Roberds SL, Leturcq F, Allamand V, Piccolo F, Jeanpierre M, Anderson RD, Lim LE, Lee JC, Tomé FMS, Romero NB, et al.: Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell 1994, 78:625-633.
41. Lim LE, Duclos F, Broux O, Bourg N, Sunada Y, Allamand V, Meyer J, Richard I, Tome F, Fardeau M, et al.: β-sarcoglycan (43 DAG): characterization and involvement in a recessive form of limb-girdle muscular dystrophy linked to chromosome 4q12. Nature Genet 1995, 11:257-265. Another dystrophin associated protein is identified as a cause of autosomal recessive LGMD.
42. Bönnemann CG, Modi R, Noguchi S, Mizuno Y, Yoshida M, Gussoni E, McNally EM, Duggan DJ, Angelini C, Hoffman EP, et al.: β-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nature Genet 1995, 11:266-273 Another dystrophin-associated protein is identified as a cause of autosomal recessive LGMD.
43. Nigro V, de Sa Moriera E, Piluso G, Vainzof M, Belsito A, Politano L, Puca AA, Passos Bueno MR, Zatz M: The 5q autosomal recessive limb-girdle muscular dystrophy (LGMD 2F) is caused by a mutation in the δ-sarcoglycan gene. Nature Genet 1996, 14:195-198. Another dystrophin-associated protein is found to be a cause of autosomal recessive LGMD.
44. Helbling-Leclerc A, Zhang X, Topaloglu H, Cruaud C, Tesson F, Weissenbach J, Tome FM, Schwartz K, Fardeau M, Tryggvason K, et al.: Mutations in the laminin alpha-2 chain gene (LAMA2) cause merosindeficient congenital muscular dystrophy. Nature Genet 1995, 11:216-218. Confirmation that one type of CMD is caused by a defect in lamimn alpha-2 chain, the extracellular attachment site of the dystrophin-glycoprotein complex.
45. Ervasti JM, Campbell KP: A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol 1993, 122:809-823.
46. Beggs AH, Kunkel LM: Improved diagnosis of Duchenne/Becker muscular dystrophy. J Clin Invest 1990, 85:613-619.
47. Chamberlain JS, Gibbs RA, Ranier JE, Caskey CT: Multiplex PCR for the diagnosis of Duchenne muscular dystrophy. In PCR Protocols: A Guide to Methods and Applications. Edited by Innis MA, Gelfand DH, Sninsky JT, White TJ, New York: Academic Press; 1990:272-281
48. Monaco AP, Bertelson CJ, Liechti GS, Moser H, Kunkel LM: An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988, 2:90-95.
49. Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, Meng G, Muller CR, Lindlof M, Kaariamen H, et al.: The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 1989, 45:498-506.
50. Gardner RJ, Bobrow M, Roberts RM: The identification of point mutations in Duchenne muscular dystrophy patients by using reverse-transcription PCR and the protein-truncation test. Am J Hum Genet 1995, 57:311-320.
51. Vainzof M, Passos-Bueno MR, Moreira ES, Pavanello RCM, Marie SK, Anderson LVB, Bönnemann CG, McNally EM, Nigro V, Kunkel LM, et al.: The sarcoglycan complex in the six autosomal recessive limb-girdle muscular dystrophies. Hum Mol Genet 1996, 5:1963-1969.
52. Lyon MF X-chromosome inactivation and developmental patterns in mammals. Biol Rev Camb Philos Soc 1972, 47:1-35.
53. Mirabella M, Servidei S, Manfredi G, RICCI E, Frustaci A, Bertini E, Rana M, Tonali P: Cardiomyopathy may be the only clinical manifestation in female carriers of Duchenne muscular dystrophy. Neurology 1993, 43:2342-2345.
54. Michels VV, Pastores GM, Moll PP, Driscoll DJ, Miller FA, Burnett JC, Rodeheffer RJ, Tajik TA, Beggs AH, Kunkel LM, et al.: Dystrophin analysis in idiopathic dilated cardiomyopathy. J Med Genet 1993, 30:955-957.
55. Kunkel LM, Snyder JR, Beggs AH, Boyce FM, Feener CA: Searching for dystrophin gene deletions in patients with atypical presentations. In Etiology of Human Disease at the DNA Level. Edited by Lindsten J, Pettersson U. New York: Raven Press; 1991:51-59.
56. van der Kooi AT, Ledderhof TM, de Voogt WG, Res CJ, Bouwsma G, Troost D, Busch HF, Becker AE, de Visser M: A newly recognized autosomal dominant limb girdle muscular dystrophy with cardiac involvement. Ann Neurol 1996, 39:636-642. Phenotypic characterization of a large family with a dominantly inherited form of LGMD that is associated with cardiac conduction system abnormalities, resulting in dysrhythmias. atrioventricular block, and sudden death. The pattern of cardiac involvement resembles myotonic dystrophy and EDMD.
57. van der Kooi AJ, van Meegan M, Ledderhof TM, McNally EM, DeVisser M, Bolhuis PA: Genetic localization of a newly recognized autosomal dominant limb girdle muscular dystrophy with cardiac involvement (LGMD1B) to chromosome 1q11-21. Am J Hum Genet 1997, 60:891-895.
58. Fardeau M, Hillaire D, Mignard C, Feingold N, Feingold J, Mignard D, de Ubeda B, Collin H, Tomé FMS, Richard I. et al.: Juvenile limb girdle muscular dystrophy: clinical, histopathological and genetic data from a small community living in the Reunion Island. Brain 1996, 119:295-308.
59. Richard I, Broux O, Allamand V, Fougerousse F, Chiannilkulchai N, Bourg N, Brenguier L, Devaud C, Pasturaud C, Roudaut C, et al.: Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995, 81:27-40.
60. Sorimachi H, Toyama-Sorimachi N, Saido TC, Kawasaki H, Sugita H, Miyasaki M, Arahata K, Ishiura S, Suzuki K: Muscle-specific calpain, p94, is degraded by autolysis immediately after translation, resulting in disappearance from muscle. J Biol Chem 1993, 268:10593-10605.
61. Sorimachi H, Kinbara K, Kimura S, Takahashi M, Ishiura S, Sasagawa N, Sorimachi N, Shimada H, Tagawa K, Maruyama K, et al.: Muscle-specific calpain, p94, responsible for limb-girdle muscular dystrophy type 2A, associates with connectin through IS2, a p94-specific sequence. J Biol Chem 1995, 270:31158-31162.
62. Fadic R, Sunada Y, Waclawik AJ, Buck S, Lewandoski PJ, Campbell KP, Lotz BP: Brief report: deficiency of a dystrophin-associated glycoprotein (adhalin) in a patient with muscular dystrophy and cardiomyopathy. N Engl J Med 1996, 334:362-366. The first report in humans implicating the sarcoglycan complex as a primary cause of cardiomyopathy in a teenage boy with mild LGMD. The BIO 14.6 hamster, an animal model for autosomal recessive muscular dystrophy and cardiomyopathy, was recently shown to have a primary deficiency of δ-sarcoglycan (see Nigro et al. [Hum Mol Genet 1997, 16:601-608]).
63. Mizuno Y, Noguchi S, Yamamoto H, Yoshida M, Suzuki A, Hagiwara Y, Hayashi YK, Arahata K, Nonaka I, Hirai S, et al.: Selective defect of sarcoglycan complex in severe childhood autosomal recessive muscular dystrophy muscle. Biochem Biophys Res Commun 1994, 203:979-983.
64. Roberds SL, Ervasti JM, Anderson RD, Ohlendieck K, Kahl SD, Zoloto D, Campbell KP: Disruption of the dystrophin-glycoprotein complex in the cardiomyopathic hamster. J Biol Chem 1993, 268:11469-11499.
65. Nigro V, Okazaki Y, Belsito A, Piluso G, Matsuda Y, Politano L, Nigro G, Ventura C, Abbondanza C, Molinari AM, et al.: Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet 1997, 16:601-608.
66. Arikawa E, Hoffmam EP, Kaido M, Nonaka I, Sugita H, Arahata K: The frequency of patients with dystrophin abnormalities in a limb-girdle patient population. Neurology 1991, 41.1491-1496.
67. Cil E, Topaloglu H, Caglar M, Ozme S: Left ventricular structure and function by echocardiography in congenital muscular dystrophy. Brain Dev 1994, 16:301-303.
68. Dubowitz V: 41 st ENMC international workshop on congenital muscular dystrophy. Neuromuscul Disord 1996, 6:295-306.
69. Reed UC, Marie SK, Vainzof M, Salum PB, Levy JA, Zatz M, Diament A: Congenital muscular dystrophy with cerebral white matter hypodensity: correlation of clinical features and merosin deficiency. Brain Dev 1996, 18:53-58.
70. Prelle A, Medori R, Moggio M, Chan HW, Gallanti A, Scarlato G, Bonilla E Dystrophin deficiency in a case of congenital myopathy. J Neurol 1992, 239:76-78.
71. Buxton J, Shelbourne P, Davies J, Jones C, Van Toneren T, Aslanidis C, de Jong P, Jansen G, Anvret M, Riley B, et al.: Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy. Nature 1992, 355:547-548.
72. Brook JD, Currach ME, Harley HG, Buckler AJ, Church D, Aburatani H, Hunter K, Stanton VP, Thirion J-P, Hudson T, et al.: Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992, 68:799-808.
73. Fu Y-H, Pizzuti A, Fenwick RG, King J, Rajnarayan S, Dunne PW, Dubel J, Nasser GA, Ashizawa T, de Jong P, et al.: An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992, 255:1256-1258.
74. Madehaven M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, Neiville C, Narang M, Barcelo J, O'Hoy K, et al.: Myotonic dystrophy mutation: an unstable CTG repeat in the 3-prime untranslated region of the gene. Science 1992, 255:1253-1255.
75. Harley HG, Rundle SA, MacMillan JC, Myring J, Brook JD, Reardon W, Fenton I, Shaw DJ, Harper PS: Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. Am J Hum Genet 1993, 52:1164-1174.
76. Wong L-JC, Ashizawa T, Monckton DG, Caskey CT, Richards CS: Somatic heterogeneity of the CTG repeat in myotonic dystrophy is age and size dependent. Am J Hum Genet 1995, 56:114-122.
77. Martorell L, Martinez JM, Carey N, Johnson K, Baiget M: Comparison of CTG repeat length expansion and clinical progression of myotonic dystrophy over a five year period. J Med Genet 1995, 32:593-596.
78. Ashizawa T, Dubel JR, Harati Y: Somatic instability of CTG repeat in myotonic dystrophy. Neurology 1993, 43:2674-2678.
79. Lavedan C, Hofmann-Radvanyi H, Shelbourne P, Rabes J-P, Duros C, Savoy D, Dehaupas I, Luce S, Johnson K, Junien C: Myotonic dystrophy: size- and sex-dependent dynamics of CTG meiotic instability, and somatic mosaicism. Am J Hum Genet 1993, 52:875-883.
80. Anvret M, Ahlberg G, Grandell U, Hedberg B, Johnson K, Edstrom L: Larger expansions of the CTG repeat in muscle compared to lymphocytes from patients with myotonic dystrophy. Hum Mol Genet 1993, 2:1397-1400.
81. Phillips MF, Harper PS: Cardiac disease in myotonic dystrophy. Cardiovasc Res 1997, 33:13-22.
82. Tokgozoglu LS, Ashizawa T, Pacifico A, Armstrong RM, Epstein HF, Zoghbi WA: Cardiac involvement in a large kindred with myotonic dystrophy: quantitative assessment and relation to size of CTG repeat expansion. JAMA 1995, 274:813-819.
83. Child JS, Perloff JK: Myocardial myotonia in myotonic muscular dystrophy. Am Heart J 1995, 129:982-990.
84. Melacini P, Villanova C, Menegazzo E, Novelli G, Danieli G, Rizzoli G, Fasoli G, Angelini C, Buja C1 Miorelli M, et al.: Correlation between cardiac involvement and CTG trinucleotide repeat length in myotonic dystrophy. J Am Coll Cardiol 1995, 25:239-245.
85. Maeda M, Taft CS, Bush EW, Holder E, Bailey WM, Neville H, Perryman MB, Bies RD: Identification, tissue-specific expression, and subcellular localization of the 80- and 71-kDa forms of myotonic dystrophy kinase protein. J Biol Chem 1995, 270:20246-20249.
86. Whiting FJ, Waring J, Tamai K, Somerville MJ, Hincke M, Staines WA, Ikeda J-E, Korneluk RG: Characterization of myotonic dystrophy kinase (DMK) protein in human and rodent muscle and central nervous tissue. Hum Mol Genet 1995, 4:1063-1072.
87. Salvatori S, Biral D, Furlan S, Marin O: Identification and localization of the myotonic dystrophy gene product in skeletal and cardiac muscles. Biochem Biophys Res Commun 1994, 203:1365-1370.
88. van der Ven PFM, Jansen G, van Kuppevelt THMSM, Perryman MB, Lupa M, Dunne PW, ter Laak HJ, Jap PHK, Veerkamp JH, Epstein HF, et al.: Myotonic dystrophy kinase is a component of neuromuscular junctions. Hum Mol Genet 1993, 2:1889-1894.
89. Wang J, Pegoraro E, Menegazzo E, Gennarelli M, Hoop RC, Angelini C, Hoffman EP: Myotonic dystrophy: evidence for a possible dominantnegative RNA mutation. Hum Mol Genet 1995, 4:599-606.
90. Wang Y-H, Griffith J: Expanded CTG triplet blocks from the myotonic dystrophy gene create the strongest known natural nucleosome positioning elements. Genomics 1995, 25:570-573.
91. Boucher CA, King SK, Carey N, Krahe R, Winchester CL, Rahman S, Creavin T, Meghji T, Bailey MES, Chartier FL, et al.: A novel homeodomain-encoding gene is associated with a large CpG island interrupted by the myotonic dystrophy unstable (CTG)n repeat. Hum Mol Genet 1995, 4:1919-1925.
92. Brink PA, Ferreira A, Moolman JC, Weymar HW, van de Merwe PL, Corfield VA: Gene for progressive familial heart block type 1 maps to chromosome 19q13. Circulation 1995, 91:1633-1640.
93. Jansen G, Groenen PJTA, Bachner D, Jap PHK, Coerwinkel M, Oerlemans F, van den Broek W, Gohlsch B, Pette D, Plomb JJ, et al.: Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice. Nature Genet 1996, 13:316-322. Neither the overexpression of Mt-PK in transgenic mice nor the absence of Mt-PK in knockout mice is able to reproduce the myotonic dystrophy phenotype, suggesting that an interspecies difference is preventing the myotonic dystrophy phenotype from being expressed in mice or that the CTG repeat expansion is required to cause disease expression.
94. Reddy S, Smith DB, Rich MM, Leferovich JM, Reilly P, Davis BM, Tran K, Rayburn H, Bronson R, Cros D, et al.: Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy. Nature Genet 1996, 13:325-335. Unlike Jansen et al. (Nature Genet 1996, 13:316-322) these authors find that mice that have had their Mt-PK gene knocked out develop a myopathy. However, these mice lack other features of myotonic dystrophy, suggesting that a simple loss of function may not explain the myotonic dystrophy phenotype in humans.
95. Merlini L, Granata C, Dominici R, Bonfiglioli S: Emery-Dreifuss muscular dystrophy: report of five cases in a family and review of the literature. Muscle Nerve 1986, 9:481-485.
96. Emery AEH: Emery-Dreifuss muscular syndrome. J Med Genet 1989, 26:637-641.
97. Voit T, Krogmann H, Lenard G: Emery-Dreifuss muscular dystrophy: disease spectrum and differential diagnosis. Neuropediatrics 1988, 19:62-71.
98. Bione S, Maestrini E, Rivella S, Mancini M, Regis S, Romeo G, Toniolo D: Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nature Genet 1994, 9:323-327.
99. Manilal S, Nguyen TM, Sewry CA, Morris GE: The Emery-Dreifuss muscular dystrophy protein, emerin, is a nuclear membrane protein. Hum Mol Genet 1996, 5:801-808. One of two papers (see Nagano et al. [Nature Genet 1996, 12:254-259]) showing by immunocytochemistry and cell fractionation that emerin is located at the nuclear membrane in normal individuals and is absent in patients with EDMD. This localization pattern suggests that emerin's function is quite different from that of the dystrophin-glycoprotein complex or Mt-PK.
100. Nagano A, Koga R, Ogawa M, Kurano Y, Kawada J, Okada R, Hayashi YK, Tsukahara T, Arahata K: Emerin deficiency at the nuclear membrane in patients with Emery-Dreifuss muscular dystrophy. Nature Genet 1996, 12:254-259. One of two papers (see Manilal et al. [Hum Mol Genet 1996, 51:801-808]) showing by immunocytochemistry and cell fractionation that emerin is located at the nuclear membrane in normal individuals and is absent in patients with EDMD. This localization pattern suggests that emerin's function is quite different from that of the dystrophin-glycoprotein complex or Mt-PK.
101. Foisner R, Gerace L: Integral membrane proteins of the nuclear envelope interact with lamins and chromosomes, and binding is modulated by mitotic phosphorylation. Cell 1993, 73:1267-1279.
102. Bione S, Small X, Aksmanovic VMA, D'Urso M, Ciccodicola A, Merlini L, Morandi L, Kress W, Yates JR, Warren ST. et al.: Identification of new mutations in the Emery-Dreifuss muscular dystrophy gene and evidence for genetic heterogeneity of the disease. Hum Mol Genet 1995, 4:1859-1863.
103. Nigro V, Bruni P, Ciccodicola A, Politano L, Nigro G, Cappa V, Covone AE, Romeo G, D'Urso M: SSCP detection of novel mutations in patients with Emery-Dreifuss muscular dystrophy: definition of a small C-terminal region required for emerin function. Hum Mol Genet 1995, 4:2003-2004.
104. Klauck SM, Wilgenbus P, Yates JRW, Muller CR, Poustka A: Identification of novel mutations in three families with Emery-Dreifuss muscular dystrophy. Hum Mol Genet 1995, 4:1853-1857.
105. Partridge TA, Morgan JE, Coulton GR, Hoffman EP, Kunkel LM: Conversion of mdx myofibers from dystrophin negative to positive by injection of normal myoblasts. Nature 1989, 337:176-179.
106. Phelps SF, Hauser MA, Cole NM, Rafael JA, Hinkel RT, Faulkner JA, Chamberlain JS: Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 1995, 4:1251-1258.
107. Wells DJ, Wells KE, Asante EA, Turner G, Sunada Y, Campbell KP, Walsh FS, Dickson G: Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Hum Mol Genet 1995, 4:1245-1250.
108. Deconinck N, Ragot T, Marechal G, Perricaudet M, Gillis JM: Functional protection of dystrophic (mdx) mouse muscles after adenovirus-mediated transfer of a dystrophin minigene. Proc Natl Acad Sci U S A 1996, 93:3570-3574.
109. Tinsley JM, Potter AC, Phelps SR, Fisher R, Trickett JI, Davies KE: Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin minigene. Nature 1996, 384:349-353.
110. Mendell JR, Kissel JT, Amato AA, King W, Signore L, Prior TW, Sahenk Z, Benson S, McAndrew PE, Rice R, et al.: Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med 1995, 333:832-838.
111. Amalfitano A, Chamberlain JS: Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy. Gene Ther 1997, 4:258-263.
112. Vainzof M, Passos-Bueno R, Man N, Zatz M: Absence of correlation between utrophin localization and quantity and the clinical severity in Duchenne/Becker dystrophies. Am J Med Genet 1995, 58:305-309.